Outset Medical, Inc. (OM): Nasdaq/NYSE listing notice — Outset Medical receives second Nasdaq delisting notice; FY2024 revenue $113.7M, down 13%

Outset Medical, Inc.

Nasdaq notified Outset on Feb 24, 2025 of non-compliance with $1.00 minimum bid price; 180-day cure period until Aug 25, 2025.
Stockholders to vote on reverse stock split (ratio 1:10 to 1:15) at special meeting March 5, 2025.
FY2024 total revenue $113.7M, down 12.8% from $130.4M in 2023; product revenue fell 21.7% to $81.0M.
Net loss narrowed to $128.0M ($2.46 loss per share) from $172.8M ($3.48) in 2023; cash rose to $124.0M from $68.5M.
Term loan balance increased to $197.4M from $130.1M; accumulated deficit reached $1.09B.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Outset Medical, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: minimum bid price
Rules: 5450(a)(1), 5810(c)(3)(A)

Exact text from the filing

February 24, 2025, the Company received a second notice (the “Notice”) from Nasdaq of failure to comply with the minimum bid price requirement. The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Select Market, which will continue to trade on the Nasdaq Global Select Market. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial compliance period of 180 calendar days, or until August 25, 2025, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Outset Medical, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-036741

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.